Eu Yan Sang International

Richard Eu Yee Ming, the fourth-generation Chairman, leads strategic and investment decisions for the family holding company. His son Richie Eu, as Managing Director of Mergers and Acquisitions, handles deal execution. Following the April 2024 sale of an 86% stake to Mitsui & Co. and Rohto Pharmaceutical, investment decisions are now subject to the governance structure agreed with the new majority owners, per the firm's official communications.

It functions as both. The firm operates a TCM retail and clinic network across five Asian markets while also managing a portfolio of commercial and industrial real estate assets. The 2024 divestment of majority control to Mitsui and Rohto does not eliminate the family's operating involvement — Richard Eu and his son remain in management roles, and the family retains a minority equity stake alongside the operating business.

The wealth originated from Traditional Chinese Medicine retailing, founded by Eu Kong in Perak, Malaya, in 1879. His son Eu Tong Sen expanded the business into a regional chain and diversified into real estate, tin mining, and rubber. The family fortune consolidated through multiple generations, with the modern entity restructured under Richard Eu during the 2016 privatization.

Richard Eu led a consortium including Tower Capital Asia and Temasek-linked Blanca Investments to delist Eu Yan Sang from the Singapore Exchange in a deal valued at approximately S$196 million. The move consolidated family and partner control, removed public-market reporting obligations, and allowed the business to pursue longer-horizon strategic initiatives without quarterly earnings pressure, per public record.

The sale reduced the family's stake to a minority position while retaining operational leadership. Mitsui & Co. and Rohto Pharmaceutical now hold 30% and 60% respectively, with the management team continuing under Richard Eu. The transaction likely shifts the family's investment posture from dominant owner to co-investor alongside strategic corporate partners, with potential redeployment of sale proceeds into new investment vehicles.

Yes. The family channels philanthropy through the Eu Yan Sang Charitable Foundation and the Joseph William Yee Eu Foundation. Richard Eu has also contributed to the SIM People Development Fund. These structures are legally distinct from the operating business and investment holdings.

The core operating footprint covers Singapore, Hong Kong, Malaysia, Macau, and China. Real estate holdings are concentrated in Singapore and Hong Kong. The 2024 partnership with Japanese corporate investors Mitsui and Rohto introduces a new strategic axis, with potential expansion into Japan and greater distribution reach across Asia-Pacific, per the firm's post-transaction announcements.